Vienna Vaccine Safety Initiative

Recent papers from Vienna Vaccine Safety Initiative

1. Second regulatory workshop on utilising in silico models to expedite vaccine development, testing, and lifecycle management - an expert meeting reportVaccine · 2026
2. Dupilumab for the treatment of eczema molluscatum: A pediatric case report and systematic literature reviewJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026
3. Modelling the Cost-Effectiveness of a Placental Malaria Vaccine in Sub-Saharan AfricaVaccines · 2026
4. Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research NetworkJMIR Public Health and Surveillance · 2026
5. Assessing Readiness for Future Maternal Malaria Vaccines: Knowledge, Practices, and Vaccine Attitudes Among Women of Reproductive Age in MalawiVaccines · 2026
6. Immunization strategies to prevent malaria in pregnancy – a multistakeholder workshopVaccine · 2026
7. Dermatologie unter der Sonne – auf Mission in den TropenJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026
8. Placental malaria: a systematic review and meta-analysis of global burden, risk factors, and maternal and foetal outcomesJournal of Global Health · 2025
9. Seroprevalence of antibodies to Plasmodium falciparum transmission-blocking target proteins Pfs230D1M and Pfs48/45 in Tanzanian populations of diverse malaria transmission intensityFrontiers in Immunology · 2025
10. Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infantsNature Communications · 2025
11. Learning from Disengagements: An Analysis of Safety Driver Interventions During Remote Driving2025
12. Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies – A stakeholder meeting reportBiologicals · 2025
13. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trialsThe Lancet Microbe · 2025
14. Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical TrialVaccines · 2025
15. Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine InfrastructureVaccines · 2024
16. Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential2024
17. Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infectionFrontiers in Immunology · 2024
18. How to develop a controlled human infection model for Clostridioides difficileClinical Microbiology and Infection · 2024
19. Advancing Vaccine Strategies for Combatting Placental Malaria: A Path to Effective ImplementationInternational Journal of Biomedical and Clinical Analysis · 2024
20. Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challengeImmunity · 2024